Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Using the human tumor clonogenic assay technique, the effects of Mitomycin C plus either alpha-interferon or gamma-interferon were studied against five human tumor xenografts serially transplanted into nude mice (three gastric and two colon cancers). When the survival fraction found with the drug combination was smaller than the multiplication of survival fractions with either drug alone, the combined effect was defined as synergism. Similarly, antagonistic effect was defined when the survival fraction of drug combination was larger than the larger one observed in either interferon or Mitomycin C alone. Four out of five human tumor xenografts (three gastric and one colon cancers) showed synergistic effects in combination of alpha-interferon with Mitomycin C. Though two gastric cancer xenografts exhibited synergistic effects in combination of gamma-interferon with Mitomycin C, antagonistic effects, which was not found in combination of alpha-interferon with Mitomycin C, were observed in one gastric cancer and one colon cancer xenografts.
 ...
PMID:In vitro chemosensitivity tests on human tumor xenografts by clonogenic assay: the combined use of mitomycin C with alpha-interferon or gamma-interferon. 393 33

CEA producing cell lines were established from human gastric cancer (HGC-Y1), pancreatic cancer (HPC-Y9) and lung cancer (HLC-Y1). The culture medium was used RPMI-1640 supplemented with 10% fetal bovine serum. The secretion of carcinoembryonic antigen (CEA) into the spent medium from these cultured cell lines was modified by several factors, such as theophylline, cyclic AMP (cAMP), dibutyryl cyclic AMP (dbcAMP), Bromodeoxyuridine (BrdUrd), dimethyl sulfoxide (DMSO), Prostaglandin E2 (PGE2) and human interferon (INF). CEA secretion was enhanced by theophylline, cAMP, PGE2 and INF. Theophylline had an optimal dose to maximally enhance CEA secretion. cAMP and INF apparently enhanced CEA secretion dose dependently. PGE2 appeared to enhance CEA secretion, although cell growth was markedly suppressed dose dependently, dbcAMP, DMSO and BrdUrd did not affect CEA secretion. Here, the kinetics of CEA secretion was discussed.
 ...
PMID:Factors affecting the CEA secretion of human adenocarcinoma cell lines into the spent medium. 631 8

A clinical study on human lymphoblastoid interferon (HLBI) in various advanced malignant diseases was performed. HLBI was administered to a total of 25 patients with various advanced malignant diseases in order ot investigate antitumor effect and toxicity. The diseases evaluated were as follows: 8 multiple myeloma (MM), 2 chronic lymphocytic leukemia (CLL), 2 adult T cell leukemia (ATL), 1 acute lymphocytic leukemia (ALL), 8 breast cancer, 3 gastric cancer and 1 ovarian cancer. Twenty-three patients received either 3 million or 6 million units of HLBI by daily intramuscular injection or every other day. One patient with ATL received 18 million units of HLBI by i. v. daily and 1 patient with ALL received 30.32 million units of HLBI i. v. daily. Tumor regression (PR) was observed in 2 patients with MM, each one patient with ATL and ALL, respectively. Major toxicities were pyrexia, myelosuppression, general malaise and G.I. toxicity. Several patients showed abnormality of hepatic or renal function. Two patients who received HLBI for more than a year developed cardiac toxicity.
 ...
PMID:[Clinical trial of human lymphoblastoid interferon on advanced malignancy]. 635 2

Since interferon (IFN) has a mechanism of action very different from chemotherapeutic agents, it is possible that a combination of two may be of therapeutic value. The authors studied increased cytotoxic effects of anticancer drugs by IFN on human tumors xenografts in nude mice. Tumor used in this study were "SH-10", "S-7379" (gastric cancer) and "O-7294" (malignant melanoma), serially transplanted subcutaneously. IFN was injected, 5 X 10(5) mu/mouse, every day for 2 weeks and a single drug was administered 3 times every fourth day. Cytotoxic effect was determined by tumor size on day 16 after treatment. Of the 7 drugs, MMC and ADM were most effective. Other drugs showed a slight inhibition of tumor growth by combination therapy with drugs and IFN.
 ...
PMID:[Increased cytotoxic effects of various anticancer drugs by alpha-interferon (HLBI) on human tumor xenografts in nude mice]. 643 98

Natural killer activity of lymphocyte against M-HeLa or MKN-28 cells was measured in the gastric cancer tissue, regional lymph nodes, spleen and peripheral blood, and also the influences of injection of Nocardia CWS into the tumor was studied. Tumor infiltrating lymphocyte showed higher rates of T and T gamma cells than the lymphocyte of normal gastric tissue, nearly the same value as the lymphocyte in peripheral blood. NK activity of the lymphocyte in the peripheral blood of the gastric cancer patient showed a significant decrease compared to that of the normal subject. NK activity of the tumor infiltrating lymphocyte was markedly lower than that of the lymphocyte in peripheral blood, and was at the same level as that of the normal stomach and the lymph node. Endoscopic injection of N-CWS into the gastric cancer tissue intensified the cytotoxicity of lymphocytes in the cancer tissue and regional lymph nodes to MKN-28 cells derived from gastric cancer 5 to 17 days later, however, the activity against M-HeLa did not augment. Human fibroblast interferon (interferon beta) increased NK activity of lymphocytes in peripheral blood and spleen, but showed no influence on the activity of lymphocytes in the gastric cancer tissue and the regional lymph nodes.
 ...
PMID:[Distribution of lymphocyte subpopulation and natural killer activity in gastric cancer tissue, normal stomach and various tissues of gastric cancer patients]. 661 84

The effects of chemotherapy for lung metastasis in 284 cancer patients using various anti-tumor drugs, including classic ones and modern active agents for the past 18 years, were presented. Lung metastasis for lung cancer was excluded. The response was achieved in cervical carcinoma of the uterus (17/62, 27%), endometrial carcinoma of the uterus (1/7, 14%), colorectal cancer (6/39, 15%), breast cancer (5/28, 18%) and stomach cancer (4/28, 14%). A high response was achieved in myosarcoma (5/12, 42%), testicular cancer (5/11, 45%) and also in ovarian cancer (3/10, 30%). Though there were few cases, a high response was achieved in malignant melanoma (2/3), choriocarcinoma (2/4) and esophageal cancer (1/3). In total patients the response rate was 20%. In these cases a complete response was achieved in 4 cervical cancers; one testicular cancer, ovarian cancer, esophageal cancer and renal cancer, respectively. However, the effect was temporary and no longterm survivor was observed except for one case of renal cancer treated continuously with interferon (3 X 10(6) units daily) and showing complete remission after 7 months of therapy. The effect of chemotherapy for lung metastasis was compared between nodular metastasis (NM) and lymphagiosis carcinomatosa (LC). In cervical carcinoma of the uterus, the response rate in NM (39%) was higher than in LC (11%). However, no difference was observed in breast cancer (NM 15%, LC 13%) nor in stomach cancer (NM 13%, LC 18%).
 ...
PMID:[Chemotherapy for metastatic lung cancer]. 687 21

Human fibroblast interferon(HFIF) was used in 26 patients with various malignant diseases, most of whom had previous chemotherapy. The dosages used were 3 X 10(6) IU or 6 X 10(6) IU of HFIF i. v. daily. Out of 24 evaluable patients, there were 2 partial remissions (CLL 1 and multiple myeloma 1), and 7 stable diseases (multiple myeloma 2, stomach cancer 2, non-Hodgkin's lymphoma 1, CLL 1 and malignant melanoma 1). The majority of the patients experienced fever exceeding 38 degrees C and chills, which became uncommon within several days of treatment. Other side effects included myelosuppression, general malaise, anorexia, hepatic dysfunction and renal dysfunction, which were mild and tolerable.
 ...
PMID:[Clinical effects of human fibroblast interferon on malignant tumors]. 718 62

Human stomach cancer cells (MKN, KATO cells) were infected with Urabe strain and wild type of mumps virus at an input multiplicity of 0.01. Both Urabe strains and wild type of mumps virus propagated rapidly in both cells and more than 10(7) p.f.u./ml of infectious virus was released. Moreover, all cultures were led to the establishment of persistent infection. These persistently infected cells were maintained under the absence of anti-serum. In all of the cultures, mumps viral antigens were detected in almost all of the cells and 10(5) - 10(7) p.f.u./ml of infectious virus was constantly released. Furthermore, interferon was not detected in the culture fluid and carried viruses had similar plaquing efficiencies at both 33 degrees C and 39 degrees C.
 ...
PMID:[Growth of mumps virus in human stomach cancer cell lines. I. Establishment of persistent infections (author's transl)]. 732 6

Since the peritoneal cavity is the most common site of initial recurrence in patients after surgery for gastric cancer, an intraperitoneal (IP) adjuvant treatment was tested in patients with resected gastric cancer with serosal involvement. Between March 1986 and September 1991, 44 consecutive patients with resected T3/T4-N0/N+ gastric cancer were given an IP combination, including cisplatin or carboplatin, etoposide, and alpha interferon-2b. The overall survival of these patients was compared with that observed in 47 historical controls (admitted to the same institutions from 1983 to 1986) with similar prognostic characteristics, who had not received adjuvant treatment after surgery. No major complication relating to the IP route was observed. Mild to moderate abdominal pain occurred in nine patients. Grade 3-4 myelotoxicity occurred in 14 patients. Interferon had to be reduced in five patients and suspended in one because of severe fatigue. Emesis occurred in 23/28 patients given cisplatin and 9/16 given carboplatin. At the time of this analysis (September 1992) median follow-up was 42 months (range 12-78) in the group receiving IP treatment, and 97 months (range 74-128) in the historical controls. There had been 20 deaths among treated patients compared with 36 in the control group. The 5-year estimated survival rate was significantly better in the patients who received IP adjuvant treatment (44% +/- 9 versus 23% +/- 6; P = 0.016). Using the Cox proportional hazard model with a backward procedure to correct for the influence of prognostic pretreatment variables, IP treatment again afforded a significant advantage in terms of survival (P = 0.04). Adjuvant IP immunochemotherapy appears to improve prognosis compared with historical controls in patients having operable gastric cancer with serosal infiltration.
 ...
PMID:Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement. 787 82

A total of 23 advanced gastric cancer patients older than 65 years received 500 mg/m2 5-fluorouracil i.v. on days 2-4, 120 mg/m2 vepesid i.v. on days 2-4, 150 mg/m2 6S-leucovorin on days 2-4, and 5 MU/m2 interferon alpha-2b on days 1-5, with cycles being repeated every 3 weeks. Toxicity was severe at an interferon (IFN) dose of 5 MU/m2; only one patient tolerated this dose. In 18 patients an IFN dose of 3 MU/m2 and in 3 other patients a dose of 4 MU/m2 could be given without producing toxicity. At an IFN dose of 5 MU/m2 the most common toxicities encountered were stomatitis (grade 4 in 1 patient and grade 3 in 12 patients), leukopenia (grade 4 in 1 patient and grade 3 in 5 patients), and thrombocytopenia (grade 3 in 3 patients). Two patients achieved a complete response and eight showed a partial response, resulting in an overall response rate of 45% [95% confidence interval (CI), 25%-64%]. The median survival was 7 months for all patients and 9 months for responding patients. In conclusion, without substantially increasing the toxicity, IFN can be added to the etoposide/leucovorin/5-fluorouracil combination, at a dose of 3 MU/m2. To verify the possible enhancement by IFN of the activity of this combination, a randomized trial is under way.
 ...
PMID:Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. 817 5


<< Previous 1 2 3 4 5 6 7 8 9 Next >>